Rheumatology International

, Volume 28, Issue 3, pp 225–231 | Cite as

Abundant expression of tetraspanin CD9 in activated osteoclasts in ovariectomy-induced osteoporosis and in bone erosions of collagen-induced arthritis

  • Kaori Iwai
  • Masaru IshiiEmail author
  • Shiro Ohshima
  • Kunio Miyatake
  • Yukihiko Saeki
Original Article


Tetraspanin CD9 has been shown to be critically involved in multinucleation and cell fusion during osteoclastogenesis, however, its in vivo pathophysiological role in bone-resorbing disorders such as osteoporosis and rheumatoid arthritis, has not been elucidated. To investigate the involvement of tetraspanin CD9 in bone destruction in such diseases, we examined the expression and distribution of tetraspanin CD9 using murine experimental models of osteoporosis and arthritis. In results, CD9 protein is abundantly expressed on the activated osteoclasts in the bone tissues whose trabeculae are severely reduced in ovariectomy-induced osteoporosis. The expression of CD9 is also detected at the sites of bone erosion in arthritic lesions of collagen-induced arthritis (CIA), where tartate-resistant acid phosphatase (TRAP) staining-positive activated osteoclasts are present. These data suggest that tetraspanin CD9 play important roles in bone destructions in osteoporosis and arthritis, and therefore, functional alterations of tetraspanin CD9 may have therapeutic potential in such bone-resorptive disorders.


Osteoclast Tetraspanin Osteoporosis Rheumatoid arthritis Immunohistochemistry 



We thank Ms. Sachiyo Uesugi (Department of Clinical Research, Osaka Minami Medical Center) for her secretary assistances. This work is supported by a Grant-in-Aid from the Ministry of Health, Labor and Welfare of Japan (001) (to Y. S.), a Grant-in-Aid for the Encouragement of Young Scientists (17790170) (to M. I) from the Ministry of Education, Science, Sports and Culture of Japan, and by a Grant-in-Aid from Ichiro Kanehara Foundation (to M.I), by a Grant-in-Aid from Takeda Science Foundation (to M. I.), and by a Grant-in-Aid from Kanae Foundation for Socio-Medical Sciences (to M. I.).


  1. 1.
    Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504–1508PubMedCrossRefGoogle Scholar
  2. 2.
    Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638–649PubMedCrossRefGoogle Scholar
  3. 3.
    Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342PubMedCrossRefGoogle Scholar
  4. 4.
    Johnston CC, Hui SL, Witt RM, Appledorn R, Baker RS, Longcope C (1985) Early menopausal changes in bone mass and sex steroids. J Clin Endocrinol Metab 61:905–911PubMedCrossRefGoogle Scholar
  5. 5.
    Slemenda C, Hui SL, Longcope C, Johnston CC (1987) Sex steroids and bone mass. A study of changes about the time of menopause. J Clin Invest 80:261–269Google Scholar
  6. 6.
    Bromley M, Bertfield H, Evanson JM, Woolley DE (1985) Bidirectional erosion of cartilage in rheumatoid knee joints. Ann Rheum Dis 44:676–681PubMedCrossRefGoogle Scholar
  7. 7.
    Kuratani T, Nagata K, Kukita T, Hotokebuchi T, Nakashima A, Iijima T (1988) Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. Ann Rheum Dis 13:751–759Google Scholar
  8. 8.
    Han X, Sterling H, Chen Y, Saginario C, Brown EJ, Frazier WA et al (2000) CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem 275:37984–37992PubMedCrossRefGoogle Scholar
  9. 9.
    Vignery A (2005) Macrophage fusion: are somatic and cancer cells possible partners? Trends Cell Biol 15:188–193PubMedCrossRefGoogle Scholar
  10. 10.
    Boucheix C, Rubinstein E (2001) Tetraspanins. Cell Mol Life Sci 58:1189–1205PubMedCrossRefGoogle Scholar
  11. 11.
    Hemler ME (2003) Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol 19:397–422PubMedCrossRefGoogle Scholar
  12. 12.
    Hemler ME (2005) Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 6:801–811PubMedCrossRefGoogle Scholar
  13. 13.
    Tarrant JM, Robb L, van Spriel AB, Wright MD (2003) Tetraspanins: molecular organizers of the leukocyte surface. Trends Immunol 24:610–617PubMedCrossRefGoogle Scholar
  14. 14.
    Ishii M, Iwai K, Koike M, Ohshima S, Kudo-Tanaka E, Ishii T, Mima T, Katada Y, Miyatake K, Uchiyama Y, Saeki Y (2006) RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis. J Bone Miner Res 21:965–76PubMedCrossRefGoogle Scholar
  15. 15.
    Trentham DE, Townes AS, Kang AH (1977) Autoimmunity to type II collagen in an experimental model of arthritis. J Exp Med 146:857–868PubMedCrossRefGoogle Scholar
  16. 16.
    Stuart JM, Townes AS, Kang AH (1982) Nature and specificity of the immune response to collagen in type II collagen-induced arthritis in mice. J Clin Invest 69:673–683PubMedGoogle Scholar
  17. 17.
    Marks SC Jr, Grolman ML (1987) Tartrate-resistant acid phosphatase in mononuclear and multinuclear cells during the bone resorption of tooth eruption. J Histochem Cytochem 35:1227–1230PubMedGoogle Scholar
  18. 18.
    Raisz LG (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115:3318–3325PubMedCrossRefGoogle Scholar
  19. 19.
    Parfitt AM, Villanueva AR, Foldes J, Rao DS (1995) Relations between histologic indices of bone formation: implications for the pathogenesis of spinal osteoporosis. J Bone Miner Res 10:466–473PubMedCrossRefGoogle Scholar
  20. 20.
    Gass M, Dawson-Hughes B (2006) Preventing osteoporosis-related fractures: an overview. Am J Med 119(4 Suppl 1):S3–S11PubMedCrossRefGoogle Scholar
  21. 21.
    Francucci CM, Camilletti A, Boscaro M (2005) Raloxifene and cardiovascular health: its relationship to lipid and glucose metabolism, hemostatic and inflammation factors and cardiovascular function in postmenopausal women. Curr Pharm Des 11:4187–4206PubMedCrossRefGoogle Scholar
  22. 22.
    Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221–1230PubMedCrossRefGoogle Scholar
  23. 23.
    Lorenzo JA, Naprta A, Rao Y, Alander C, Glaccum M, Widmer M, et al (1988) Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology 139:3022–3025CrossRefGoogle Scholar
  24. 24.
    Gao Y, Qian WP, Dark K, Toraldo G, Lin AS, Guldberg RE et al (2004) Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc Natl Acad Sci USA 101:16618–16623PubMedCrossRefGoogle Scholar
  25. 25.
    Takayanagi H, Sato K, Takaoka A, Taniguchi T (2005) Interplay between interferon and other cytokine systems in bone metabolism. Immunol Rev 208:181–93PubMedCrossRefGoogle Scholar
  26. 26.
    Boyce BF, Li P, Yao Z, Zhang Q, Badell IR, Schwarz EM, O’Keefe RJ, Xing L (2005) TNF-alpha and pathologic bone resorption. Keio J Med 54:127–131PubMedCrossRefGoogle Scholar
  27. 27.
    Tanaka S, Nakamura K, Takahasi N, Suda T (2005) Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 208:30–49PubMedCrossRefGoogle Scholar
  28. 28.
    Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163–196PubMedCrossRefGoogle Scholar
  29. 29.
    Maini RN, Taylor PC (2000) Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 51:207–229PubMedCrossRefGoogle Scholar
  30. 30.
    Dinarello CA (2005) Blocking IL-1 in systemic inflammation. J Exp Med 201:1355–1359PubMedCrossRefGoogle Scholar
  31. 31.
    Nishimoto N, Kishimoto T. (2004) Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 4:386–391PubMedCrossRefGoogle Scholar
  32. 32.
    Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G (2004) Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 50:277–2790PubMedCrossRefGoogle Scholar
  33. 33.
    Wada T, Nakashima T, Hiroshi N, Penninger JM (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12:17–25PubMedCrossRefGoogle Scholar
  34. 34.
    Nakashima T, Wada T, Penninger JM (2003) RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 15:280–287PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Kaori Iwai
    • 1
  • Masaru Ishii
    • 1
    • 2
    Email author
  • Shiro Ohshima
    • 1
  • Kunio Miyatake
    • 1
  • Yukihiko Saeki
    • 1
  1. 1.Department of and Rheumatology and Clinical ResearchNational Hospital Organization Osaka Minami Medical CenterOsakaJapan
  2. 2.Department of Clinical ResearchNational Hospital Organization Osaka Minami Medical CenterOsakaJapan

Personalised recommendations